Influence of tumor necrosis factor-α gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation

被引:22
作者
Densem, CG
Hutchinson, IV
Yonan, N
Brooks, NH
机构
[1] Wythenshawe Hosp, Dept Cardiol, Cardiothorac Transplant Unit, Manchester M23 9LT, Lancs, England
[2] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England
关键词
D O I
10.1016/S1053-2498(01)00358-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Tumor necrosis factor-alpha (TNF-alpha) has been implicated in cardiovascular disease. Polymorphism of the TNF-alpha gene promoter region (position -308) influences an individual's production of TNF-alpha. This affects susceptibility to acute rejection after cardiac transplantation. Because the highest serum levels of TNF-alpha have been found in recipients with cardiac transplant vasculopathy and because TNF-alpha blockade can prevent the disease in rabbits, we investigated the effect of TNF-alpha promoter polymorphism on the development of vasculopathy in human cardiac allograft recipients Methods: Using sequence-specific primers to the TNF-alpha gene and polymerase chain reaction, the genotypes of 147 cardiac transplant recipients and 134 heart donors were identified. An association was sought between the presence of high-producing (A homozygotes, GA heterozygotes) or low-producing (G homozygotes) TNF-alpha genotype and the development of coronary vasculopathy, diagnosed by routine surveillance coronary angiography. Results: We found that 31.9% of recipients and 27.0% of donors were high TNF-alpha producers. The presence of the high-producing TNF-alpha allele led to an earlier diagnosis of vasculopathy; 3.42 years (+/- 91.3 days) vs 3.84 years (+/- 76.3 days) for high- and low-producing cardiac graft recipients, respectively; 3.52 years (+/- 87.3 days) vs 3.78 years (+/- 77.4 days) for high- and low-producing donor grafts, respectively. However, neither of these differences were significant. By Kaplan Meier actuarial analysis and log-rank test, TNF-alpha polymorphism had no effect on the freedom from vasculopathy when considering either recipient (p = 0.99) or donor (p = 0.86) TNF-alpha genotype. Multivariate analysis identified increasing donor age and the number of acute rejection episodes of International Society for Heart and Lung Transplantation grade 3 or greater as independent risk factors for vasculopathy in both the recipient and donor cohorts. Conclusions: Polymorphism at position -308 in the promoter region of the TNF-alpha gene fails to predict the development of cardiac transplant-related vasculopathy and cannot be used as a genetic risk marker. This may be because of the effects of immunosuppressive treatment.
引用
收藏
页码:1265 / 1273
页数:9
相关论文
共 54 条
[1]   Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation [J].
Andreassen, AK ;
Nordoy, I ;
Simonsen, S ;
Ueland, T ;
Müller, F ;
Froland, SS ;
Gullestad, L ;
Aukrust, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (05) :604-608
[2]   DETECTION AND LOCALIZATION OF TUMOR NECROSIS FACTOR IN HUMAN ATHEROMA [J].
BARATH, P ;
FISHBEIN, MC ;
CAO, J ;
BERENSON, J ;
HELFANT, RH ;
FORRESTER, JS .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (05) :297-302
[3]  
BARSARAN Y, 1993, ANGIOLOGY, V44, P332
[4]   The effect of polymorphisms in tumor necrosis factor-α, interleukin-10, and transforming growth factor-β1 genes in acute hepatic allograft rejection [J].
Bathgate, AJ ;
Pravica, V ;
Perrey, C ;
Theraponods, G ;
Plevris, JN ;
Hayes, PC ;
Hutchinson, IV .
TRANSPLANTATION, 2000, 69 (07) :1514-1517
[5]   CONTROL OF CACHECTIN (TUMOR-NECROSIS-FACTOR) SYNTHESIS - MECHANISMS OF ENDOTOXIN RESISTANCE [J].
BEUTLER, B ;
KROCHIN, N ;
MILSARK, IW ;
LUEDKE, C ;
CERAMI, A .
SCIENCE, 1986, 232 (4753) :977-980
[6]  
BILLINGHAM ME, 1995, TRANSPLANT P, V27, P2013
[7]  
BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19
[8]  
BOLLIG S, 1992, TRANSPLANTATION, V52, P283
[9]   TUMOR NECROSIS FACTOR CACHECTIN INCREASES PERMEABILITY OF ENDOTHELIAL-CELL MONOLAYERS BY A MECHANISM INVOLVING REGULATORY G-PROTEINS [J].
BRETT, J ;
GERLACH, H ;
NAWROTH, P ;
STEINBERG, S ;
GODMAN, G ;
STERN, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (06) :1977-1991
[10]  
BRINKMAN BMN, 1995, IMMUNOLOGY, V86, pA75